These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 18398097)

  • 1. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial.
    von Minckwitz G; Kümmel S; Vogel P; Hanusch C; Eidtmann H; Hilfrich J; Gerber B; Huober J; Costa SD; Jackisch C; Loibl S; Mehta K; Kaufmann M;
    J Natl Cancer Inst; 2008 Apr; 100(8):542-51. PubMed ID: 18398097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab added to neoadjuvant chemotherapy for breast cancer.
    Bear HD; Tang G; Rastogi P; Geyer CE; Robidoux A; Atkins JN; Baez-Diaz L; Brufsky AM; Mehta RS; Fehrenbacher L; Young JA; Senecal FM; Gaur R; Margolese RG; Adams PT; Gross HM; Costantino JP; Swain SM; Mamounas EP; Wolmark N
    N Engl J Med; 2012 Jan; 366(4):310-20. PubMed ID: 22276821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
    Hudis CA; Seidman AD; Baselga J; Raptis G; Lebwohl D; Gilewski T; Currie V; Moynahan ME; Sklarin N; Fennelly D
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):18-23. PubMed ID: 8643965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.
    Nabholtz JM; Smylie M; Mackey JR; Noel D; Paterson AH; al-Tweigeri T; Au D; Sansregret E; Delorme F; Riva A
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):37-41. PubMed ID: 9364541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast conservation after induction chemotherapy for locally advanced breast cancer.
    Kling KM; Ostrzega N; Schmit P
    Am Surg; 1997 Oct; 63(10):861-4. PubMed ID: 9322658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial.
    Bear HD; Tang G; Rastogi P; Geyer CE; Liu Q; Robidoux A; Baez-Diaz L; Brufsky AM; Mehta RS; Fehrenbacher L; Young JA; Senecal FM; Gaur R; Margolese RG; Adams PT; Gross HM; Costantino JP; Paik S; Swain SM; Mamounas EP; Wolmark N
    Lancet Oncol; 2015 Sep; 16(9):1037-1048. PubMed ID: 26272770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective, randomized Phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma.
    Blajman C; Balbiani L; Block J; Coppola F; Chacon R; Fein L; Bonicatto S; Alvarez A; Schmilovich A; Delgado FM
    Cancer; 1999 Mar; 85(5):1091-7. PubMed ID: 10091793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The feasibility of minimally invasive surgery for stage IIA, IIB, and IIIA breast carcinoma patients after tumor downstaging with induction chemotherapy.
    Vlastos G; Mirza NQ; Lenert JT; Hunt KK; Ames FC; Feig BW; Ross MI; Buzdar AU; Singletary SE
    Cancer; 2000 Mar; 88(6):1417-24. PubMed ID: 10717625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer.
    Buzdar AU; Singletary SE; Theriault RL; Booser DJ; Valero V; Ibrahim N; Smith TL; Asmar L; Frye D; Manuel N; Kau SW; McNeese M; Strom E; Hunt K; Ames F; Hortobagyi GN
    J Clin Oncol; 1999 Nov; 17(11):3412-7. PubMed ID: 10550135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group.
    Miller KD; McCaskill-Stevens W; Sisk J; Loesch DM; Monaco F; Seshadri R; Sledge GW
    J Clin Oncol; 1999 Oct; 17(10):3033-7. PubMed ID: 10506597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) with a rotational crossing and a sequential intensification regimen in advanced breast cancer: a prospective randomized study.
    Cocconi G; Bisagni G; Bella M; Acito L; Anastasi P; Carpi A; Di Costanzo F; Frassoldati A; Mosconi A; Borrini A; Buzzi P
    Am J Clin Oncol; 1999 Dec; 22(6):593-600. PubMed ID: 10597744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical phase II-evaluation of neoadjuvant, cytostatic combination chemotherapy with docetaxel and epidoxorubicin in female breast cancer patients (T1-4, N0-2, M0)].
    Wenzel C; Schmidinger M; Locker GJ; Taucher S; Gnant M; Jakesz R; Steger GG
    Wien Klin Wochenschr; 1999 Oct; 111(20):843-50. PubMed ID: 10586489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pattern of failure in patients with inflammatory breast cancer treated by alternating radiotherapy and chemotherapy.
    Thomas F; Arriagada R; Spielmann M; Mouriesse H; Le Chevalier T; Fontaine F; Tursz T
    Cancer; 1995 Dec; 76(11):2286-90. PubMed ID: 8635033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: an Intergroup study.
    Fetting JH; Gray R; Fairclough DL; Smith TJ; Margolin KA; Citron ML; Grove-Conrad M; Cella D; Pandya K; Robert N; Henderson IC; Osborne CK; Abeloff MD
    J Clin Oncol; 1998 Jul; 16(7):2382-91. PubMed ID: 9667255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value of estrogenic recruitment before chemotherapy: first randomized trial in primary breast cancer.
    Bontenbal M; van Putten WL; Burghouts JT; Baggen MG; Ras GJ; Stiegelis WF; Beudeker M; Janssen JT; Braun JJ; van der Linden GH; van der Velden PC; van Geel AN; Helle P; Leisink M; Foekens JA; Klijn JG
    J Clin Oncol; 2000 Feb; 18(4):734-42. PubMed ID: 10673514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and pathological response to primary chemotherapy in operable breast cancer.
    Chollet P; Charrier S; Brain E; Curé H; van Praagh I; Feillel V; de Latour M; Dauplat J; Misset JL; Ferrière JP
    Eur J Cancer; 1997 May; 33(6):862-6. PubMed ID: 9291806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8.
    Norris B; Pritchard KI; James K; Myles J; Bennett K; Marlin S; Skillings J; Findlay B; Vandenberg T; Goss P; Latreille J; Rudinskas L; Lofters W; Trudeau M; Osoba D; Rodgers A
    J Clin Oncol; 2000 Jun; 18(12):2385-94. PubMed ID: 10856098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18.
    Fisher B; Brown A; Mamounas E; Wieand S; Robidoux A; Margolese RG; Cruz AB; Fisher ER; Wickerham DL; Wolmark N; DeCillis A; Hoehn JL; Lees AW; Dimitrov NV
    J Clin Oncol; 1997 Jul; 15(7):2483-93. PubMed ID: 9215816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective randomized trial.
    Joensuu H; Holli K; Heikkinen M; Suonio E; Aro AR; Hietanen P; Huovinen R
    J Clin Oncol; 1998 Dec; 16(12):3720-30. PubMed ID: 9850014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tc-99m sestamibi scintimammography in the evaluation of response of breast carcinoma to chemotherapy.
    Joaquim AI; Sagarra AJ; Ramos CD; Coudry R; Sagarra RA; Camargo EE
    Clin Nucl Med; 1997 Sep; 22(9):638-40. PubMed ID: 9298303
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.